Skip to main content
DaShenLin Pharmaceutical Group Co., Ltd. logo

DaShenLin Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 603233 ISIN · CNE100002RG2 LEI · 300300TO4U1GUOTTHK82 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,440 across all filing types
Latest filing 2026-05-18 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 603233

About DaShenLin Pharmaceutical Group Co., Ltd.

https://www.dslyy.com

DaShenLin Pharmaceutical Group Co., Ltd. is a large-scale enterprise specializing in the retail and distribution of pharmaceutical and health-related products. The company operates an extensive network of pharmacies, providing a wide range of products including prescription medications, over-the-counter drugs, traditional Chinese medicine, medical devices, and nutritional supplements. Beyond retail operations, the group is involved in pharmaceutical manufacturing, wholesale distribution, and logistics management. It emphasizes professional pharmaceutical services, offering health consultations and chronic disease management to its customers. By leveraging an integrated supply chain and digital health platforms, the company provides comprehensive healthcare solutions and improves accessibility to medical supplies.

Recent filings

Filing Released Lang Actions
大参林医药集团股份有限公司2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement detailing the resolutions and voting results of the 2025 annual shareholders’ meeting, including attendance, vote counts, and approval of each proposal. This fits the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-05-18 Chinese
北京市金杜（广州）律师事务所关于大参林医药集团股份有限公司2025年年度股东会的法律意见书
AGM Information Classification · 87% confidence The document is a formal legal opinion letter issued by the company’s external law firm regarding the 2025 Annual General Meeting (AGM) of Dashenlin Pharmaceutical Group, reviewing the convening procedure, vote mechanics, and results. It is part of the AGM materials (legal opinions are commonly circulated as part of the meeting packet). It is not a financial report, earnings release, or standalone regulatory compliance note, but specifically an AGM‐related document. Therefore, it fits the AGM Information category (AGM-R).
2026-05-18 Chinese
大参林医药集团股份有限公司关于召开2025年度暨2026年第一季度业绩说明会的公告
Regulatory Filings
2026-05-08 Chinese
大参林医药集团股份有限公司2025年度股东会会议材料
Regulatory Filings
2026-05-08 Chinese
大参林医药集团股份有限公司关于2026年度“提质增效重回报”行动方案的公告
Regulatory Filings Classification · 75% confidence The document is a Shanghai Stock Exchange styled “公告” outlining a board‐approved “2026年度‘提质增效重回报’专项行动方案” (quality/efficiency improvement and shareholder return action plan). It is not a financial report (10-K, IR), not a dividend notice alone (DIV), not a proxy statement (PSI), nor a management change (MANG) or financing update (CAP). It presents operational strategy, governance enhancements, and investor return measures in a general announcement. As it does not fit any specific form category, it falls under the miscellaneous “Regulatory Filings” category (RNS).
2026-04-23 Chinese
大参林医药集团股份有限公司关于子公司申请银行综合授信额度及提供担保的公告
Capital/Financing Update Classification · 85% confidence The document is an official corporate announcement detailing the company’s subsidiaries applying for a combined bank credit facility and the parent company’s provision of guarantees up to CNY 8.82 billion. It outlines financing arrangements rather than reporting audited results, dividends, or share transactions. This is a financing update regarding debt facilities and guarantees, matching the Capital/Financing Update category (CAP).
2026-04-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.